Physician profile

Daniel Lee Miller

Thoracic Surgery (Cardiothoracic Vascular Surgery) · Marietta, GA

NPI 1831288430

$236,684.30

in general payments reported to CMS, 2019-2025

34 companies · $18K in 2025

The $18K reported for 2025 was more than what 93% of Thoracic Surgery (Cardiothoracic Vascular Surgery) providers received nationally (typical 2025 total: $796).

See the full distribution for Thoracic Surgery (Cardiothoracic Vascular Surgery)

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$95,083.29
Travel and Lodging$17,378.08
Food and Beverage$4,867.64
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$2,625.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Ethicon INC. $75,215.00 2019-2024 Echelon Flex, Echelon Endopath, Harmonic
Atricure, INC. $49,486.00 2019-2025 Atricure Cryoice Cryosphere Cryoablation System, Synergy Ablation System, Atricure Cryoice Cryoablation System (Cryo2)
Medical Device Business Services, INC. $40,336.37 2019-2024 Echelon Flex, Echelon Endopath, Harmonic
Acumed LLC $39,084.52 2019-2025 Biobridge, Ribloc, Osteomed
Pacira Pharmaceuticals Incorporated $10,640.95 2019-2021
Tela Bio, INC. $8,516.17 2020-2022
Ethicon US, LLC $8,135.18 2020-2025 Vistaseal, Echelon Endopath, Dermabond
Medela Ag $1,500.00 2022
Davol INC. $634.88 2023-2025 Progel Applicator Spray Tips, Tridyne Vascular Sealant, Arista Ah Flexitip
Astrazeneca Pharmaceuticals LP $525.01 2019-2025 Airsupra
Intuitive Surgical, INC. $514.71 2020-2022
Merck Sharp & Dohme LLC $363.83 2019-2024 Keytruda
Medtronic, INC. $295.27 2022-2024 Signia
Aroa Biosurgery Incorporated $225.84 2022-2023
Abbvie INC. $174.65 2019-2025
Show all 34 companies
CompanyGeneral paymentsYearsTop products
Solventum Corporation $157.88 2024-2025 V.A.C. Granufoam, Activ.A.C., V.A.C. Veraflo Cleanse Choice
E.R. Squibb & Sons, L.L.C. $152.79 2019-2022
Covidien LP $147.70 2019
Osteomed LLC $97.34 2022
Novartis Pharmaceuticals Corporation $85.21 2019-2020
Amgen INC. $62.01 2019
On Target Laboratories, INC $60.29 2025 Cytalux
Team 1, LLC $37.39 2024
Regeneron Healthcare Solutions, INC. $30.42 2020
Boehringer Ingelheim Pharmaceuticals, INC. $26.12 2019
Janssen Biotech, INC. $24.90 2021
Rigel Pharmaceuticals, INC. $24.71 2019
Eisai INC. $24.26 2019
Kci USA, INC. $21.37 2023 V.A.C.Instill, V.A.C. Veraflo Cleanse Choice, Prevena
Cook Medical LLC $20.26 2020
Fortovia Therapeutics, INC. $19.04 2019
Smith+Nephew, INC. $17.81 2025 Pico
Seagen INC. $13.22 2021
Pfizer INC. $13.20 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Daniel Lee Miller

$236,684.30

in general payments reported 2019-2025

Years
2019-2025
Top company
Ethicon INC.
Context
The $18K reported for 2025 was more than what 93% of Thoracic Surgery (Cardiothoracic Vascular Surgery) providers received nationally (typical 2025 total: $796).

https://glasscript.com/doctor/355511/daniel-lee-miller

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.